Compounds > azomycin
Page last updated: 2024-08-21

azomycin and th 302

azomycin has been researched along with th 302 in 70 studies

Research

Studies (70)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's59 (84.29)24.3611
2020's11 (15.71)2.80

Authors

AuthorsStudies
Chen, D; Curd, J; Duan, JX; Li, J; Li, S; Matteucci, M; Zhang, J1
De Raeve, H; Handisides, DR; Hart, CP; Hu, J; Liu, Q; Menu, E; Sun, JD; Van Camp, B; Van Valckenborgh, E; Vande Broek, I; Vanderkerken, K1
Bendell, JC; Borad, MJ; Burris, HA; Chiorean, EG; Infante, JR; Jones, SF; Kroll, S; Lacouture, ME; Langmuir, VK; Lee, H; Lewandowski, K; Molina, JR; Ramanathan, RK; Tibes, R; Weiss, GJ1
Adkins, D; Butrynski, JE; Chawla, SP; Cranmer, LD; Ganjoo, KN; Kroll, S; Langmuir, VK; Lorente, G; Okuno, SH; Rushing, D1
Cai, X; Duan, JX; Jiao, H; Jung, D; Lin, L; Matteucci, M1
Duan, JX; Jiao, H; Jung, D; Matteucci, M; Wang, R2
Anderson, RF; Banica, M; Bhupathi, D; Cai, X; Duan, JX; Evans, JW; Glazer, PM; Guise, CP; Hart, CP; Lan, L; Lorente, G; Maroz, A; Matteucci, MD; Meng, F; Mowday, AM; Patterson, AV; Stachelek, GC1
Ahluwalia, D; Ammons, WS; Curd, JG; Duan, JX; Ferraro, D; Hart, CP; Liu, Q; Matteucci, MD; Sun, JD; Wang, J; Wang, Y1
Ahluwalia, D; Ammons, WS; Baker, AF; Cranmer, LD; Curd, JG; Duan, JX; Ferraro, D; Hart, CP; Liu, Q; Matteucci, MD; Sun, JD; Wang, J; Wang, Y1
Baker, AF; Cárdenas-Rodríguez, J; Cornnell, H; Galons, JP; Gillies, RJ; Li, Y; Pagel, MD1
Moyer, MW1
De Bruyne, E; De Bryune, E; De Raeve, H; Handisides, D; Hart, CP; Hu, J; Menu, E; Van Camp, B; Van Valckenborgh, E; Vanderkerken, K; Xu, D; Xu, S1
Ashoorzadeh, A; Ding, K; Guise, CP; Lin, WH; Mowday, AM; Patterson, AV; Smaill, JB; Wu, DH; Yuan, R1
Hart, CP; Hsu, YC; Johnson, MK; Lal, D; Portwood, S; Vargas, R; Wang, ES; Wetzler, M1
Saggar, JK; Tannock, IF2
Adkins, DR; Butrynski, JE; Chawla, SP; Cranmer, LD; Ganjoo, KN; Hendifar, AE; Kroll, S; Okuno, SH; Reed, DR; Van Tine, BA1
Choudhuri, R; DeGraff, W; Devasahayam, N; Gillies, RJ; Hart, CP; Kesarwala, AH; Kishimoto, S; Krishna, MC; Matsumoto, S; Matsuo, M; Mitchell, JB; Munasinghe, JP; Saito, K; Subramanian, S; Takakusagi, Y; Wojtkowiak, JW1
Atkins, GJ; DeNichilo, M; Evdokiou, A; Findlay, DM; Hay, S; Ingman, W; Labrinidis, A; Liapis, V; Panagopoulos, V; Ponomarev, V; Zannettino, ACW; Zinonos, I1
Bahary, N; Borad, MJ; Chiorean, EG; Cohn, AL; Del Prete, SA; Dragovich, T; Eng, C; Kroll, S; Rarick, M; Reddy, SG; Rosen, PJ; Ryan, DP; Schelman, WR; Sigal, D; Stephenson, J; Ulrich, B; Uronis, HE1
Bailey, KM; Baker, AF; Cornnell, HH; Gillies, RJ; Hart, CP; Ibrahim-Hashim, A; Leos, R; Martinez, GV; Wojtkowiak, JW; Zhang, X1
Ahluwalia, D; Bhupathi, D; Hart, CP; Li, W; Liu, Q; Meng, F; Ruprell, AS; Sun, JD; Wang, Y1
Biemans, R; Dubois, LJ; Hart, CP; Lambin, P; Lieuwes, NG; Peeters, SG; Sun, JD; van Elmpt, W; van Stiphout, RG; Windhorst, AD; Yaromina, A; Zegers, CM1
Ahluwalia, D; Bhupathi, D; Hart, CP; Liu, Q; Matteucci, MD; Meng, F; Sun, JD; Wang, Y1
Choy, E; Eisinger-Mathason, TS; Hart, CP; Lee, HJ; Lee, YJ; Park, DJ; Simon, MC; Tap, WD; Yoon, C; Yoon, SS1
Brown, KR; Goldstein, DP; Gu, Y; Hunter, FW; Joshi, N; Ketela, T; Koritzinsky, M; Moffat, J; Rischin, D; Shalev, Z; Solomon, B; Sreebhavan, S; Vellanki, RN; Wang, J; Weinreb, I; Wilson, WR; Wouters, BG; Young, RJ1
Andreeff, M; Bankson, JA; Benito, J; Bhattacharya, PK; Cortes, JE; Davis, RE; Hart, CP; Harutyunyan, KG; Jacamo, R; Konoplev, S; Konopleva, M; Lee, J; Lu, H; Ma, H; Marszalek, JR; Matre, P; McQueen, T; Millward, NZ; Mu, H; Protopopova, M; Ramirez, MS; Shi, YX; Velez, J; Volgin, A1
Baruchel, S; Kumar, S; Marrano, P; Thorner, P; Wu, B; Zhang, L1
Atkins, GJ; DeNichilo, M; Evdokiou, A; Findlay, DM; Hay, S; Ingman, W; Labrinidis, A; Liapis, V; Panagopoulos, V; Ponomarev, V; Zannettino, AC; Zinonos, I; Zysk, A1
Ahluwalia, D; Ferraro, DJ; Hart, CP; Jung, D; Liu, Q; Matteucci, MD; Sun, JD; Wang, Y1
Andreeff, M; Badar, T; Benito, JM; Borthakur, G; Cortes, JE; Faderl, S; Handisides, DR; Harutyunyan, K; Jabbour, E; Kantarjian, HM; Konoplev, S; Konopleva, M; Kroll, S; Pearce, T; Richie, MA; Thomas, DA1
Baker, AF; Cornnell, HH; Gillies, R; Hart, CP; Martinez, GV; Wojtkowiak, JW; Zhang, X1
Pourmorteza, M; Rahman, ZU; Young, M1
Cao, P; Do, T; Hedley, DW; Hill, RP; Lohse, I; Pintilie, M; Rasowski, J; Tsao, MS1
Brayton, CF; Chapiro, J; Cornish, TC; Duran, R; Frangakis, C; Ganapathy-Kanniappan, S; Geschwind, JF; Gorodetski, B; Hart, CP; Lin, M; Mirpour, S; Pekurovsky, V; Reyes, J; Schernthaner, RE; Sun, JD1
Berbée, M; Claessens, A; Dubois, LJ; Erdkamp, FL; Lambin, P; Larue, RT; Nap, M; Panth, KM; Peeters, SG; Schreurs, WM; Sosef, MN; Van De Voorde, L; van Elmpt, WJ; Warmerdam, FA1
Ham, SL; Joshi, R; Luker, GD; Tavana, H1
Bender, S; Grgic, I; Guckenberger, M; Nytko, KJ; Ott, J; Pruschy, M; Riesterer, O1
Endo, Y; Goto-Koshino, Y; Lai, YC; Miura, N; Nakaichi, M; Setoguchi, A; Tateno, M; Tsujimoto, H; Yamazaki, H1
Chezal, JM; Degoul, F; Jouberton, E; Maubert, E; Miot-Noirault, É; Peyrode, C; Voissiere, A1
Hart, CP; Kishimoto, S; Krishna, MC; Matsumoto, S; Mitchell, JB; Naz, S; Saito, K; Takakusagi, Y1
Atkins, GJ; DeNichilo, M; Difelice, C; Evdokiou, A; Findlay, DM; Hay, S; Ingman, W; Liapis, V; Panagopoulos, V; Ponomarev, V; Shoubridge, A; Zannettino, ACW; Zinonos, I; Zysk, A1
Constantinidou, A; van der Graaf, WTA1
Anderson, RF; Hunter, FW; Li, D1
Brenner, A; Caflisch, L; Cavazos, D; Fichtel, L; Floyd, J; Gruslova, A; Hart, CP; Huang, S; Kroll, S; Liu, Y; Lodi, A; Sun, JD; Tiziani, S; Zuniga, R1
Gendoo, DMA; Haibe-Kains, B; Haller, A; Haynes, J; Jaffray, DA; Kreso, A; Leung, C; Lima-Fernandes, E; McKee, TD; Metser, U; O'Brien, CA; Smith, M; Szentgyorgyi, E; Vines, DC; Wang, Y; Wolman, R; Wouters, BG1
He, X; Huang, Y; Liu, L; Tian, Y; Xue, C; Zhan, J; Zhang, L; Zhao, Y1
Adam, ASA; Boulghourjian, A; Caldon, CE; Cazet, AS; Conway, JRW; Croucher, DR; Da Silva, AM; Del Monte-Nieto, G; Haigh, JJ; Harvey, RP; Herrmann, D; Killen, MJ; Magenau, A; Mélénec, P; Morton, JP; Murphy, KJ; Nobis, M; Pajic, M; Pinese, M; Sansom, OJ; Shearer, RF; Timpson, P; Vennin, C; Wang, Y; Warren, SC; Zaratzian, A1
Dickson, BD; Hay, MP; Hicks, KO; Hong, CR; Hunter, FW; Jaiswal, JK; Pruijn, FB; Wilson, WR1
Bohlander, SK; Budhani, P; Butt, S; Caporiccio, L; Chaplin, JM; Chiorean, EG; Curran, MA; Grénman, RA; Hart, CP; Hicks, KO; Hong, CR; Hunter, FW; Jalal, SI; Jamieson, SM; Kakadia, PM; Kee, D; Knowlton, NS; Kondratyev, MK; Lee, TW; Li, D; Liu, A; Lynch, CR; Macann, AM; McIvor, NP; McKee, TD; Nemunaitis, JJ; Poonawala-Lohani, N; Print, CG; Senzer, NN; Shome, A; Tsai, P; Wilson, WR; Wong, WW; Wouters, BG; Zaidi, M1
Ager, C; Ai, M; Balasubramanyam, S; Bartkowiak, T; Budhani, P; Curran, MA; Jaiswal, AR; Jayaprakash, P; Li, N; Liu, A; Nicholas, C; Ning, J; Shah, K; Sheng, J; Sun, Y; Wang, G; Zal, A; Zal, T1
Dolgos, H; Dyroff, M; El Bawab, S; Gallemann, D; Hecht, S; Johne, A; Jung, D; Lüpfert, C; von Richter, O1
Hicks, KO; Hong, CR; Wilson, WR1
Ahmed, M; Ba-Alawi, W; Beltran, H; Berlin, A; Boutros, PC; Bristow, RG; Chen, S; Ci, X; Ellis, L; Fazli, L; Feng, FY; Gleave, M; Guo, H; Haibe-Kains, B; He, HH; Hua, JT; Koritzinsky, M; Li, E; Liang, Y; Lin, D; Mahamud, O; Nguyen, T; Poirier, JT; Puca, L; Rudin, CM; Sheahan, AV; Soares, F; Su, P; Tsao, MS; van der Kwast, T; Vellanki, RN; Vosoughi, A; Wang, Y; Wouters, BG; Xu, J; Xu, X; Xue, H; Zhang, S; Zhang, Y; Zoubeidi, A1
Bohlander, SK; Devaux, JBL; Hart, CP; Hickey, AJR; Hong, CR; Hunter, FW; Kakadia, PM; Ketela, TW; Khan, A; Marastoni, S; Meng, F; Print, CG; Shalev, Z; Sharma, I; Tsai, P; Wilson, WR; Wouters, BG1
Attia, S; Ballman, K; Jones, RL; Lu, Y; Pápai, Z; Reinke, D; Schöffski, P; Tap, WD; Van Tine, BA; Younger, E1
Chaplin, JM; Harms, JK; Hunter, FW; Jamieson, SMF; Kee, D; Lai, A; Lee, TW; Macann, AMJ; McIvor, NP; Wang, T; Wilson, WR1
Biemans, R; Dubois, LJ; Lambin, P; Lieuwes, NG; Marcus, D; Niemans, R; Spiegelberg, L; Theys, J; van Hoof, SJ; Verhaegen, F; Yaromina, A1
Brender, JR; Chandramouli, GVR; Kishimoto, S; Krishna, MC; Mitchell, JB; Saida, Y; Yamamoto, K1
Cheon, GJ; Kang, SY; Lee, KH; Oh, DY; Yoon, J1
Chen, J; Li, X; Li, Y; Li, Z; Ma, P; Nai, J; Qu, H; Song, Z; Tang, X; Wang, Z; Xin, H; Zhang, J1
Chen, L; Guo, J; Jiang, H; Li, X; Liu, B; Liu, J; Liu, Z; Peng, Z; Wan, C; Wang, J; Wang, S; Xie, Y; Xu, Y; Zhong, Y1
Brenner, AJ; Fichtel, L; Floyd, J; Huang, S; Kanakia, KP; Lee, EQ; Michalek, J; Reardon, D; Wen, PY1
Abdalah, MA; Budzevich, MM; Bui, MM; Dominguez-Viqueira, W; Gillies, RJ; Huang, S; Jardim-Perassi, BV; Johnson, JO; Martinez, GV; Mu, W; Poleszczuk, J; Reed, DR; Tomaszewski, MR1
An, Y; Chen, D; Ding, Y; He, C; Hu, C; Liu, D; Liu, P; Tang, Q; Wang, X; Yang, R; Yu, W; Zhang, Z1
Alonso-Gordoa, T; Benavent, M; Capdevila, J; Custodio, A; Díez, JJ; Gajate, P; García-Carbonero, R; Grande, E; Hernando, J; Lanillos, J; López, C; Molina-Cerrillo, J; Rodriguez-Antona, C; Santos, M; Sevilla, I; Teulé, A1
Angermeier, A; Della Manna, D; Larimer, BM; Li, Y; Reeves, KM; Song, PN; Sorace, AG; Wang, J; Yang, ES1
Hu, S; Li, M; Lin, Y; Lv, J; Qiao, D; Wang, S1

Reviews

2 review(s) available for azomycin and th 302

ArticleYear
Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.
    Chinese journal of cancer, 2014, Volume: 33, Issue:2

    Topics: Anthraquinones; Antineoplastic Agents; Aziridines; Cell Hypoxia; Humans; Indolequinones; Molecular Structure; NAD(P)H Dehydrogenase (Quinone); Neoplasms; Nitrogen Mustard Compounds; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; Tirapazamine; Triazines

2014
Evofosfamide, a new horizon in the treatment of pancreatic cancer.
    Anti-cancer drugs, 2016, Volume: 27, Issue:8

    Topics: Antineoplastic Agents; Humans; Nitroimidazoles; Pancreatic Neoplasms; Phosphoramide Mustards; Prodrugs; Tumor Hypoxia

2016

Trials

14 trial(s) available for azomycin and th 302

ArticleYear
Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, May-01, Volume: 17, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Cell Hypoxia; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Models, Biological; Neoplasms; Nitroimidazoles; Phosphoramide Mustards; Prodrugs

2011
A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.
    Oncology, 2011, Volume: 80, Issue:1-2

    Topics: Abscess; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cellulitis; Disease-Free Survival; Doxorubicin; Drug Eruptions; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphopenia; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neutropenia; Nitroimidazoles; Phosphoramide Mustards; Sarcoma; Stomatitis; Treatment Outcome; Young Adult

2011
Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Oct-10, Volume: 32, Issue:29

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Male; Middle Aged; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; Sarcoma; Survival Rate; Treatment Outcome

2014
Tumor hypoxia is a therapeutic target in soft-tissue sarcoma.
    Cancer discovery, 2014, Volume: 4, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Hypoxia; Doxorubicin; Humans; Nitroimidazoles; Phosphoramide Mustards; Sarcoma; Tumor Microenvironment

2014
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, May-01, Volume: 33, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Nitroimidazoles; Pancreatic Neoplasms; Phosphoramide Mustards; Proportional Hazards Models; Time Factors; Treatment Outcome; United States

2015
Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer.
    Cancer biology & therapy, 2015, Volume: 16, Issue:3

    Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA Damage; Gemcitabine; Humans; Mice; Nitroimidazoles; Paclitaxel; Phosphoramide Mustards; Xenograft Model Antitumor Assays

2015
Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.
    Cancer biology & therapy, 2016, 04-02, Volume: 17, Issue:4

    Topics: Animals; Carcinoma, Non-Small-Cell Lung; Humans; Ifosfamide; Lung Neoplasms; Mice; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; Xenograft Model Antitumor Assays

2016
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.
    American journal of hematology, 2016, Volume: 91, Issue:8

    Topics: Adult; Aged; Bone Marrow; Esophagitis; Female; Humans; Hyperbilirubinemia; Hypoxia; Leukemia; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Nitroimidazoles; Phosphoramide Mustards; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prodrugs; Salvage Therapy; Stomatitis; Young Adult

2016
A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
    BMC cancer, 2016, 08-17, Volume: 16

    Topics: Adenocarcinoma; Cell Hypoxia; Chemoradiotherapy, Adjuvant; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophagectomy; Female; Humans; Male; Nitroimidazoles; Phosphoramide Mustards; Positron-Emission Tomography; Preoperative Care; Survival Analysis; Treatment Outcome

2016
Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study.
    Neuro-oncology, 2018, 08-02, Volume: 20, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glioblastoma; Humans; Hypoxia; Male; Middle Aged; Neoplasm Recurrence, Local; Nitroimidazoles; Phosphoramide Mustards; Prognosis; Salvage Therapy

2018
Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.
    JCI insight, 2018, 08-23, Volume: 3, Issue:16

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Chemoradiotherapy; Drug Resistance, Neoplasm; Exome Sequencing; Female; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Middle Aged; Nitroimidazoles; Papillomaviridae; Phosphoramide Mustards; Prodrugs; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays; Young Adult

2018
Subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial.
    Journal of geriatric oncology, 2020, Volume: 11, Issue:3

    Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Nitroimidazoles; Phosphoramide Mustards

2020
Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma.
    Scientific reports, 2021, 01-27, Volume: 11, Issue:1

    Topics: Adult; Aged; Bevacizumab; Female; Glioblastoma; Humans; Male; Middle Aged; Nitroimidazoles; Phosphoramide Mustards; Young Adult

2021
Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial.
    The oncologist, 2021, Volume: 26, Issue:11

    Topics: Humans; Middle Aged; Neoplasms, Second Primary; Nitroimidazoles; Pancreatic Neoplasms; Phosphoramide Mustards; Progression-Free Survival; Sunitinib

2021

Other Studies

54 other study(ies) available for azomycin and th 302

ArticleYear
Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302.
    Biological trace element research, 2010, Volume: 136, Issue:3

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Enzyme Assays; Glutathione Reductase; Injections, Intraperitoneal; Liver Neoplasms, Experimental; Male; Mice; Molecular Structure; Nitroimidazoles; Phosphoramide Mustards; Thioredoxin-Disulfide Reductase; Time Factors; Treatment Outcome; Tumor Burden

2010
Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.
    Blood, 2010, Sep-02, Volume: 116, Issue:9

    Topics: Animals; Apoptosis; Blotting, Western; Bone Marrow; Caspases; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Humans; Hypoxia; Male; Mice; Mice, Inbred C57BL; Multiple Myeloma; Neovascularization, Pathologic; Nitroimidazoles; Oxygen; Phosphoramide Mustards; Prodrugs; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A

2010
Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:3

    Topics: Administration, Oral; Animals; Dogs; Drug Evaluation, Preclinical; Female; Half-Life; Humans; Hypoxia; Infusions, Intravenous; Injections, Intraperitoneal; Injections, Intravenous; Macaca fascicularis; Male; Mice; Mice, Inbred Strains; Mice, Nude; Molecular Structure; Nitroimidazoles; Phosphoramide Mustards; Predictive Value of Tests; Prodrugs; Rats; Rats, Sprague-Dawley; Species Specificity; Tissue Distribution

2012
Metabolism, pharmacokinetics and excretion of a novel hypoxia activated cytotoxic prodrug, TH-302, in rats.
    Xenobiotica; the fate of foreign compounds in biological systems, 2012, Volume: 42, Issue:4

    Topics: Animals; Bile; Cell Hypoxia; Half-Life; Male; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; Rats; Rats, Sprague-Dawley; Tissue Distribution

2012
Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:3

    Topics: Animals; Cell Hypoxia; Cell Line, Tumor; Cell Survival; CHO Cells; Comet Assay; Cricetinae; Cricetulus; DNA Damage; Dose-Response Relationship, Drug; HCT116 Cells; Histones; HT29 Cells; Humans; Inhibitory Concentration 50; Molecular Structure; Neoplasms; Nitroimidazoles; Oxidation-Reduction; Oxygen; Phosphoramide Mustards; Phosphorylation; Prodrugs; Spheroids, Cellular; Tumor Stem Cell Assay

2012
Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Feb-01, Volume: 18, Issue:3

    Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Cell Line, Tumor; Female; Humans; Immunohistochemistry; Mice; Mice, SCID; Neoplasms, Experimental; Neovascularization, Pathologic; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; Xenograft Model Antitumor Assays

2012
Metabolism and excretion of TH-302 in dogs.
    Xenobiotica; the fate of foreign compounds in biological systems, 2012, Volume: 42, Issue:7

    Topics: Animals; Area Under Curve; Dogs; Ethylamines; Feces; Nitroimidazoles; Phosphoramide Mustards

2012
TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Hypoxia; Cell Line, Tumor; Cisplatin; Deoxycytidine; Docetaxel; Drug Evaluation, Preclinical; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Mice; Mice, SCID; Nitroimidazoles; Pemetrexed; Phosphoramide Mustards; Prodrugs; Taxoids; Xenograft Model Antitumor Assays

2012
Imaging biomarkers to monitor response to the hypoxia-activated prodrug TH-302 in the MiaPaCa2 flank xenograft model.
    Magnetic resonance imaging, 2012, Volume: 30, Issue:7

    Topics: Animals; Antineoplastic Agents; Biomarkers, Pharmacological; Cell Line, Tumor; Diffusion Magnetic Resonance Imaging; Female; Mice; Mice, SCID; Nitroimidazoles; Pancreatic Neoplasms; Phosphoramide Mustards; Prodrugs; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome

2012
Targeting hypoxia brings breath of fresh air to cancer therapy.
    Nature medicine, 2012, May-04, Volume: 18, Issue:5

    Topics: Cell Hypoxia; Clinical Trials as Topic; Humans; Neoplasms; Nitroimidazoles; Phosphoramide Mustards

2012
Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:9

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred C57BL; Multiple Myeloma; Nitroimidazoles; Phosphoramide Mustards; Pyrazines; Signal Transduction

2013
Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Dec-01, Volume: 19, Issue:23

    Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; DNA Fragmentation; Female; Histones; HL-60 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Nitroimidazoles; Phosphoramide Mustards; Phosphorylation; Protein Processing, Post-Translational; Reactive Oxygen Species; Tumor Burden; Xenograft Model Antitumor Assays

2013
Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy.
    International journal of cancer, 2014, Jun-01, Volume: 134, Issue:11

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cell Hypoxia; Docetaxel; Doxorubicin; Female; Humans; Male; Mice; Mice, Nude; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; Prostatic Neoplasms; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2014
Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302.
    PloS one, 2014, Volume: 9, Issue:9

    Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Drug Synergism; Female; Humans; Mice; Mitochondria; Nitroimidazoles; Oxygen; Oxygen Consumption; Phosphoramide Mustards; Prodrugs; Pyruvic Acid; Time Factors; Xenograft Model Antitumor Assays

2014
Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma.
    Cancer letters, 2015, Feb-01, Volume: 357, Issue:1

    Topics: Animals; Apoptosis; Bone Neoplasms; Cell Hypoxia; Female; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Nitroimidazoles; Osteosarcoma; Phosphoramide Mustards; Prodrugs

2015
Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer.
    PloS one, 2014, Volume: 9, Issue:12

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Blood Circulation; Cell Hypoxia; Cell Line, Tumor; Drug Synergism; Female; Humans; Hydralazine; Hydrogen-Ion Concentration; Mice; Nitroimidazoles; Pancreatic Neoplasms; Phosphoramide Mustards; Prodrugs; Tumor Microenvironment; Xenograft Model Antitumor Assays

2014
Chemotherapy Rescues Hypoxic Tumor Cells and Induces Their Reoxygenation and Repopulation-An Effect That Is Inhibited by the Hypoxia-Activated Prodrug TH-302.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, May-01, Volume: 21, Issue:9

    Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Docetaxel; Doxorubicin; Female; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplasms, Experimental; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; Taxoids; Xenograft Model Antitumor Assays

2015
TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Jul-01, Volume: 21, Issue:13

    Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Chemoradiotherapy; Imidazoles; Lung Neoplasms; Nitroimidazoles; Phosphoramide Mustards; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Treatment Outcome; Triazoles; Xenograft Model Antitumor Assays

2015
Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.
    BMC cancer, 2015, May-21, Volume: 15

    Topics: Animals; Antineoplastic Agents; Apoptosis; CDC2 Protein Kinase; Cell Cycle Checkpoints; Cell Survival; Checkpoint Kinase 1; Colonic Neoplasms; DNA Damage; Female; Histones; HT29 Cells; Humans; Mice; Mice, Nude; Mutation; Nitroimidazoles; Phosphoproteins; Phosphoramide Mustards; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Rad51 Recombinase; Signal Transduction; Thiophenes; Tumor Suppressor Protein p53; Urea

2015
Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas.
    British journal of cancer, 2015, Jun-30, Volume: 113, Issue:1

    Topics: Activation, Metabolic; Animals; Antineoplastic Agents; Combined Modality Therapy; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Mice; Mice, Inbred BALB C; Nitroimidazoles; Phosphoramide Mustards; Sarcoma; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2015
Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs.
    Cancer research, 2015, Oct-01, Volume: 75, Issue:19

    Topics: Activation, Metabolic; Antineoplastic Agents; Biomarkers; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Chemoradiotherapy; Cyclic N-Oxides; Cytochrome P-450 Enzyme System; Head and Neck Neoplasms; High-Throughput Screening Assays; Humans; Neoplasm Proteins; Nitroimidazoles; Papillomaviridae; Papillomavirus Infections; Phosphoramide Mustards; Prodrugs; Retrospective Studies; RNA Interference; RNA, Messenger; RNA, Small Interfering; Tirapazamine; Triazines; Tumor Microenvironment; Tumor Stem Cell Assay

2015
Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Apr-01, Volume: 22, Issue:7

    Topics: Animals; Antineoplastic Agents; Bone Marrow; Cell Line, Tumor; Disease Models, Animal; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Hypoxia; Leukemia; Magnetic Resonance Imaging; Mice; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; Treatment Outcome; Tumor Microenvironment; Xenograft Model Antitumor Assays

2016
Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 06-01, Volume: 22, Issue:11

    Topics: Activation, Metabolic; Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Inhibitory Concentration 50; Mice, Inbred NOD; Mice, SCID; Neuroblastoma; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; Rhabdomyosarcoma; Topotecan; Xenograft Model Antitumor Assays

2016
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models.
    Cancer medicine, 2016, Volume: 5, Issue:3

    Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Nitroimidazoles; Paclitaxel; Phosphoramide Mustards; Tumor Burden; Xenograft Model Antitumor Assays

2016
MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts.
    PloS one, 2016, Volume: 11, Issue:5

    Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Female; Humans; Hypoxia; Magnetic Resonance Imaging; Mice; Mice, SCID; Nitroimidazoles; Pancreatic Neoplasms; Phosphoramide Mustards; Prodrugs; Time Factors; Xenograft Model Antitumor Assays

2016
Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302.
    Oncotarget, 2016, Jun-07, Volume: 7, Issue:23

    Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Cell Line, Tumor; Humans; Mice; Neoplastic Stem Cells; Nitroimidazoles; Pancreatic Neoplasms; Phosphoramide Mustards; Prodrugs; Tumor Microenvironment; Xenograft Model Antitumor Assays

2016
Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Jan-15, Volume: 23, Issue:2

    Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Circulating Tumor DNA; Combined Modality Therapy; Disease Models, Animal; Doxorubicin; Ethiodized Oil; Humans; Liver Neoplasms; Nitroimidazoles; Phosphoramide Mustards; Rabbits; Tumor Hypoxia

2017
Engineered Breast Cancer Cell Spheroids Reproduce Biologic Properties of Solid Tumors.
    Advanced healthcare materials, 2016, Volume: 5, Issue:21

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Engineering; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Extracellular Matrix Proteins; Female; Humans; Hypoxia; Neoplastic Stem Cells; Nitroimidazoles; Phosphoramide Mustards; Polymers; Prodrugs; Spheroids, Cellular; Triple Negative Breast Neoplasms

2016
The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy.
    Oncotarget, 2017, Apr-04, Volume: 8, Issue:14

    Topics: Animals; Cell Hypoxia; Cell Line, Tumor; Chemoradiotherapy; Head and Neck Neoplasms; Humans; Mice; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; Radiotherapy

2017
Hypoxia-activated prodrug TH-302 decreased survival rate of canine lymphoma cells under hypoxic condition.
    PloS one, 2017, Volume: 12, Issue:5

    Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Dogs; Gene Expression Regulation, Neoplastic; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Lymphoma; Nitroimidazoles; Phosphoramide Mustards; Platelet-Derived Growth Factor; Prodrugs; Up-Regulation; Vascular Endothelial Growth Factor A

2017
Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing.
    PloS one, 2017, Volume: 12, Issue:7

    Topics: Antineoplastic Agents; Bone Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Chondrosarcoma; Doxorubicin; Drug Screening Assays, Antitumor; Humans; Nitroimidazoles; Phosphoramide Mustards; Spheroids, Cellular; Tissue Scaffolds

2017
Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies.
    Antioxidants & redox signaling, 2018, Jan-10, Volume: 28, Issue:2

    Topics: Animals; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Disease Models, Animal; DNA Damage; Humans; Hypoxia; Mice; Nitroimidazoles; Oxidation-Reduction; Phosphoramide Mustards; Prodrugs; Radiotherapy; Tumor Burden; Xenograft Model Antitumor Assays

2018
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma.
    Cancer medicine, 2017, Volume: 6, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Humans; Nitroimidazoles; Osteosarcoma; Phosphoramide Mustards; Prodrugs; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays

2017
The fate of new fosfamides in phase III studies in advanced soft tissue sarcoma.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 84

    Topics: Antineoplastic Agents, Alkylating; Clinical Trials, Phase III as Topic; Evidence-Based Medicine; Humans; Neoplasm Staging; Nitroimidazoles; Phosphoramide Mustards; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Sarcoma; Soft Tissue Neoplasms; Survival Analysis; Time Factors; Treatment Outcome

2017
Antagonism in effectiveness of evofosfamide and doxorubicin through intermolecular electron transfer.
    Free radical biology & medicine, 2017, Volume: 113

    Topics: Antineoplastic Agents; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Clinical Trials as Topic; Doxorubicin; Drug Combinations; Electron Transport; Electrons; Epithelial Cells; Free Radicals; Humans; Kinetics; Nitroimidazoles; Oxidation-Reduction; Oxygen; Phosphoramide Mustards; Pulse Radiolysis; Treatment Failure

2017
Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 05-01, Volume: 24, Issue:9

    Topics: Animals; Biomarkers; Caspases; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Chemoradiotherapy; Colorectal Neoplasms; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Synergism; Female; Humans; Hypoxia; Male; Mice; Neoplastic Stem Cells; Nitroimidazoles; Phenotype; Phosphoramide Mustards; Positron-Emission Tomography; Prodrugs; Standard of Care; Wnt Signaling Pathway; Xenograft Model Antitumor Assays

2018
Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo.
    Cancer communications (London, England), 2018, 05-03, Volume: 38, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Cisplatin; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; Treatment Outcome; Xenograft Model Antitumor Assays

2018
Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer.
    Cell reports, 2018, 06-12, Volume: 23, Issue:11

    Topics: Animals; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Fluorescence Resonance Energy Transfer; Humans; Hypoxia; Intravital Microscopy; Mice; Mice, Inbred BALB C; Morpholines; Nanoparticles; Nitroimidazoles; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoramide Mustards; Proto-Oncogene Proteins c-akt; Pyrimidines; Signal Transduction; Transplantation, Heterologous; Tumor Microenvironment

2018
Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects.
    Biochemical pharmacology, 2018, Volume: 156

    Topics: Antineoplastic Agents; Bystander Effect; Escherichia coli Proteins; HCT116 Cells; Humans; Molecular Structure; NADPH-Ferrihemoprotein Reductase; Nitroimidazoles; Nitroreductases; Phosphoramide Mustards; Prodrugs

2018
Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy.
    The Journal of clinical investigation, 2018, 11-01, Volume: 128, Issue:11

    Topics: Adenocarcinoma; Animals; Cell Hypoxia; Cell Line, Tumor; Immunotherapy; Male; Mice; Mice, Knockout; Neoplasm Proteins; Neoplasms, Experimental; Nitroimidazoles; Phosphoramide Mustards; Prostatic Neoplasms; T-Lymphocytes

2018
A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug-Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide.
    CPT: pharmacometrics & systems pharmacology, 2018, Volume: 7, Issue:12

    Topics: Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Nitroimidazoles; Phosphoramide Mustards; Prodrugs

2018
An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect.
    Neoplasia (New York, N.Y.), 2019, Volume: 21, Issue:2

    Topics: Algorithms; Animals; Antineoplastic Agents; Biological Transport; Bystander Effect; Cell Culture Techniques; Cell Line, Tumor; Chromatography, Liquid; Humans; Hydroxylamine; Hypoxia; Models, Biological; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; Tandem Mass Spectrometry

2019
ONECUT2 is a driver of neuroendocrine prostate cancer.
    Nature communications, 2019, 01-17, Volume: 10, Issue:1

    Topics: Animals; Carcinogenesis; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Datasets as Topic; Disease Progression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neuroendocrine Tumors; Nitroimidazoles; Phosphoramide Mustards; Prostate; Prostatic Neoplasms; RNA, Small Interfering; Signal Transduction; Smad3 Protein; Transcription Factors; Up-Regulation; Xenograft Model Antitumor Assays

2019
Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of Evofosfamide.
    Molecular pharmacology, 2019, Volume: 95, Issue:6

    Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; CRISPR-Cas Systems; Electron Transport; Gene Expression Regulation; Gene Regulatory Networks; HCT116 Cells; Humans; Mitochondria; Neoplasms; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; RNA, Small Interfering; Sequence Analysis, RNA

2019
Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models.
    Cells, 2019, 07-13, Volume: 8, Issue:7

    Topics: Animals; Cytochrome P-450 Enzyme System; Head and Neck Neoplasms; Humans; Ki-67 Antigen; Mice; Mice, Inbred NOD; Nitroimidazoles; Nuclear Proteins; Phosphoramide Mustards; Squamous Cell Carcinoma of Head and Neck; Tumor Hypoxia; Xenograft Model Antitumor Assays

2019
Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2019, Volume: 141

    Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Esophageal Neoplasms; Female; Humans; Male; Mice; Nitroimidazoles; Phosphoramide Mustards; Radiation-Sensitizing Agents; Squamous Cell Carcinoma of Head and Neck

2019
Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox Status to Potentiate Radiotherapy.
    Antioxidants & redox signaling, 2021, 10-10, Volume: 35, Issue:11

    Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Humans; Mice; Neoplasms, Experimental; Nitroimidazoles; Oxidation-Reduction; Pancreatic Neoplasms; Phosphoramide Mustards; Prodrugs

2021
Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer.
    Cancer research and treatment, 2021, Volume: 53, Issue:2

    Topics: Biliary Tract Neoplasms; Cell Hypoxia; Female; Humans; Male; Middle Aged; Misonidazole; Nitroimidazoles; Phosphoramide Mustards; Positron-Emission Tomography; Prospective Studies

2021
Hypoxic targeting and activating TH-302 loaded transcatheter arterial embolization microsphere.
    Drug delivery, 2020, Volume: 27, Issue:1

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization; Cell Hypoxia; Chemoembolization, Therapeutic; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Liver Neoplasms; Microspheres; Nitroimidazoles; Phosphoramide Mustards; Rabbits

2020
Hypoxia-induced CREB cooperates MMSET to modify chromatin and promote DKK1 expression in multiple myeloma.
    Oncogene, 2021, Volume: 40, Issue:7

    Topics: Chromatin; Cyclic AMP Response Element-Binding Protein; Gene Expression Regulation, Neoplastic; Histone-Lysine N-Methyltransferase; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Intercellular Signaling Peptides and Proteins; Multiple Myeloma; Nitroimidazoles; Osteoblasts; Osteolysis; Phosphoramide Mustards; Repressor Proteins; Tumor Hypoxia; Wnt Signaling Pathway

2021
Deep-learning and MR images to target hypoxic habitats with evofosfamide in preclinical models of sarcoma.
    Theranostics, 2021, Volume: 11, Issue:11

    Topics: Animals; Artificial Intelligence; Cell Line, Tumor; Deep Learning; Disease Models, Animal; Doxorubicin; Ecosystem; Female; Humans; Hypoxia; Magnetic Resonance Imaging; Mice; Mice, Inbred C3H; Mice, SCID; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; Sarcoma; Soft Tissue Neoplasms; Xenograft Model Antitumor Assays

2021
Chitosan oligosaccharide decorated liposomes combined with TH302 for photodynamic therapy in triple negative breast cancer.
    Journal of nanobiotechnology, 2021, May-19, Volume: 19, Issue:1

    Topics: Animals; Antineoplastic Agents; Chitosan; Female; Humans; Hyaluronan Receptors; Hyaluronic Acid; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Nanomedicine; Nitroimidazoles; Oligosaccharides; Optical Imaging; Phosphoramide Mustards; Photochemotherapy; Photosensitizing Agents; Prodrugs; Triple Negative Breast Neoplasms

2021
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 01-15, Volume: 28, Issue:2

    Topics: Cell Hypoxia; CTLA-4 Antigen; Humans; Hypoxia; Misonidazole; Neoplasms; Nitroimidazoles; Phosphoramide Mustards; Positron-Emission Tomography; Programmed Cell Death 1 Receptor; Tumor Microenvironment

2022
Mitochondria-targeting multifunctional nanoplatform for cascade phototherapy and hypoxia-activated chemotherapy.
    Journal of nanobiotechnology, 2022, Jan-21, Volume: 20, Issue:1

    Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Female; Mice; Mice, Inbred C57BL; Mitochondria; Nanoparticles; Nitroimidazoles; Phosphoramide Mustards; Photochemotherapy; Prodrugs; Tissue Distribution

2022